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Abstract: Themisuse of antibiotics in health care has led to increasing levels of drug resistant infections
(DRI’s) occurring in the general population. Most technologies developed for the detection of DRI’s
typically focus on phenotyping or genotyping bacterial resistance rather than on the underlying cause
and spread of DRI’s; namely the misuse of antibiotics. An aptameric based assay has been developed
for the monitoring of ampicillin in urine samples, for use in determining optimal antibiotic dosage
and monitoring patient compliance with treatment. The fluorescently labelled aptamers were shown
to perform optimally at pH 7, ideal for buffered clinical urine samples, with limits of detection as
low as 20.6 nM, allowing for determination of ampicillin in urine in the clinically relevant range of
concentrations (100 nM to 100 µM). As the assay requires incubation for only 1 h with a small sample
volume, 50 to 150 µL, the test would fit within current healthcare pathways, simplifying the adoption
of the technology.
Keywords: ampicillin; aptamer; drug-resistant-infections; antimicrobial resistance; diagnostics; gold
nanoparticles; beta-lactamase; beta-lactam; fluorescence; urine analysis
1. Introduction
Antibiotics are used extensively for the vital treatment of bacterial infections in both humans
and animals. The misuse and overreliance upon antibiotics has accelerated the development of
antimicrobial resistance (AMR) against a large variety of commonly used antibiotics [1]. This in turn
had led to a clinical increase in difficult-to-treat drug-resistant infections (DRI’s) for multiple bacterial
strains [1–3].
β-Lactam-based antimicrobials are among the most commonly used classes of antibiotics, showing
effectiveness against a wide variety of both Gram-positive and Gram-negative bacteria [4–6]. However,
overuse of this important class of antibiotics, partly due to poor dosage management and patients
not complying with treatment, has led to the emergence of high levels of resistance [7]. For example,
it has been suggested that up to 75% of critically ill patients in intensive care may not be receiving
appropriate doses of β-lactam class antibiotics [8] and in excess of 95% of pathogenic Staphylococcus
aureus worldwide is resistant to β-lactam antibiotics [7]. This high prevalence of resistance has
dramatically restricted the use of previously common β-lactam antibiotics. Ampicillin, for example,
was the most commonly used β-lactam class antibiotic in healthcare but increasingly, pathogenic
Escherichia coli strains are showing resistance to ampicillin, decreasing effectiveness in the treatment of
common infections. The misuse and non-optimal dosage of antibiotics has therefore led to an increase
in recurrent urinary tract infections (UTI’s), with a 16.1% increase in cases of drug resistant UTI’s
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between 1990 and 2013 globally leading to over >93 million cases worldwide and 10.5 million visits to
physicians in the US alone [8,9].
Current techniques to determine resistance rely on culturing of bacterial strains in the presence
of antibiotics. While such susceptibility tests can be very accurate, they are typically slow, taking
up to 48 h [8] to achieve a definitive result. To combat the rise in DRI’s, a wide variety of tests are
being developed for the purpose of determining the presence of antimicrobial resistant pathogens in
shorter time frames and often focus on the development of new technologies [10–13] for point-of-care
diagnostics including: PCR [14,15], nucleic acid amplification techniques (NAAT) [16], rapid antibiotic
susceptibility testing [17,18], electrochemical detection [19] and SERS [20–22]. Several reviews have
also been published on this topic examining rapid point-of-care tests and their adoption for both
respiratory and urinary tract infections and their adoption into clinical pathways [11,23–26]. While
these technologies show great promise, they often require current clinical pathways within healthcare
systems to be adapted, or are deployed ineffectively, limiting their uptake [5,27–32]. Rapid adoption of
new diagnostics would thus ideally employ equipment and processes commonly found in hospital
laboratories. Furthermore, despite the importance of appropriate dosage management and patient
compliance in tackling the spread and emergence of resistance [33], the majority of these emerging
technologies focus instead on the direct detection of DRI’s and thus only partly address the misuse of
β-lactam antibiotics.
It has been suggested that a more effective approach to tackling AMR and the DRI’s caused by
this is to prevent the misuse of antibiotics in the first place. To this end, high performance liquid
chromatography (HPLC) methods in combination with various forms of detection have been applied
for determination of antibiotic concentrations in plasma samples [34–36]. While accurate, enabling
quantification on the nM to µM range on a short time scale (typically less than 20 min), these techniques
require invasive sampling to collect and process the blood plasma as well as expensive equipment and
expert users [37].
Diagnostic assays based on fluorescently labelled aptamers have the potential to satisfy the needs
for rapid detection and compatibility with established laboratory protocols, typically only requiring a
plate reader for concentration read out. DNA aptamers are single stranded DNA (ssDNA) molecules
that are capable of binding a wide range of biomarkers including microbial and viral pathogens [38–43],
and small molecules [43]. The high affinity and specificity of aptamers relates to their capability to
recognise a target molecule through interactions between the 3D conformation of the folded aptamer
and the target [44]. Given the high binding affinity and selectivity coupled with in vitro selection and
low-cost synthesis, they are ideal candidates for use in a variety of healthcare diagnostics. Furthermore,
they are compatible with a wide variety of readout systems including time resolved fluorescence [45],
magnetic resonance imaging [46,47], flow cytometry [38,48], electrochemical sensors [39,42,49], and
lateral flow devices [41,43,50].
Recently, an aptameric based assay has been developed by Song et al. for the quantification of
ampicillin in heavily processed milk in the agricultural industry using the first aptamer reported for
ampicillin detection [4]. The assay combined fluorescently-labelled aptamers specific to ampicillin that
was non-specifically bound to gold nanoparticles (AuNPs) that acted as a quencher for the fluorescent
tag. In the presence of ampicillin, the aptamer dissociates from the AuNPs, resulting in a fluorescent
readout and subsequent aggregation of the gold nanoparticles, Figure 1. The assay was demonstrated
using processed milk as a sample matrix, that was buffered to pH 8 where the signal of the fluorescent
tag was optimal and diluted to minimise potentially interfering components in the milk that otherwise
induced nanoparticle aggregation. While the assay is suitable for use in an agricultural setting, the
requirement to heavily dilute and buffer the sample would limit its use and its adaptability for use in
other settings.
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Figure 1. Schematic diagram of the ampicillin aptamer assay. The fluorescently-labelled aptamer is
initially bound, non-specifically to gold nanoparticles (AuNPs), leading to quenching of the fluorescence
label (1). In the presence of ampicillin, the aptamer dissociates from the AuNP surface in order to
selectively bind to the drug leading to an increase in the fluorescent signal (2). The intensity of the
fluorescence is proportional to the concentration of ampicillin present within the sample.
Here we show the development of an aptamer-based assay previously used in a non-clinical
setting and developing this for the optimisation of ampicillin dosage and compliance by monitoring a
patient’s urine sample. Specifically, we demonstrate a diagnostic assay based on fluorescently-labelled
aptamers that is capable of quantifying the concentration of ampicillin in clinical urine samples with a
high degree of sensitivity at clinical levels. Readout and quantification of the assay is achieved using
a standard laboratory fluorometer, requires limited pre-sample preparation and is thus suitable for
translation into established clinical pathways to support the informed use of this valuable antibiotic [4].
2. Results
2.1. Determination of Ampicillin in Buffer
The aptamer used in this work was previously reported by Song et al. [4]. The ssDNA aptamer
(3′-GCGGGCGGTTGTATAGCGG-5′) was selected against ampicillin via the SELEX technique and
was confirmed to bind to ampicillin with a high degree of sensitivity and specificity (Kd = 13.4 nM).
Initial testing of the aptamer sequence for use in clinical urine samples was performed here through
the introduction of the fluorescent fluorescein derivative, FAM, at the 5′-end of the oligonucleotide
(3′-GCGGGCGGTTGTATAGCGG-5′-FAM). Urine samples were collected anonymously from 13
healthy adult volunteers that had not shown symptoms of infection and had not taken antibiotics
within 1 month prior to the sample collection. Participants were recruited from within the University
of York. Samples were filter sterilised using 0.22 µm syringe filters to remove any cells. The urine
samples were combined to form an “average” human urine pool, which was aliquoted and stored in a
−80 ◦C freezer. The pH of the resulting urine was measured to be pH 6.7. All collection and processing
of the samples was performed and conforms to the University of York’s Ethical approval and clinical
sample handling guidelines.
The labelled aptamer strand (10 nM) was annealed at 95 ◦C for 5 min in potassium phosphate
buffer containing magnesium chloride (KPi, 100 mM + 1 mMMgCl2, pH 8), before cooling to 4
◦C.
The annealed aptamer strandswere subsequently incubatedwithAuNP’s, producing anAuNP-aptamer
conjugate with a quenched fluorescence. Ampicillin samples of known concentrations were prepared
by serial dilution of a 10 mM stock dissolved in KPi buffer (pH 8). Samples containing ampicillin (1 nM
to 1 mM) were subsequently mixed with the AuNP-aptamer conjugate in triplicate and incubated for a
further 1 h at room temperature in a 96-well plate. The fluorescent signal (λex = 487 nm, λem = 528 nm)
of the solutions was subsequently measured relative to the fluorescence intensity of a blank sample of
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buffer with no ampicillin present. The continuous band structure of the AuNPs effectively quenches
the fluorescence of the fluorescent tag when the aptamer is bound passively to its surface. Upon
incubation with ampicillin the aptamer selectively binds to the antibiotic, dissociating from the surface
of the AuNPs, allowing the fluorescence of the FAM tag to be quantified and calibrated against the
concentration of ampicillin present in the sample. An increase in the fluorescence was therefore seen
with the increasing concentration of ampicillin present in the buffer, as shown in Figure 2. We note, the
high baseline level of fluorescence is believed to be due to incomplete quenching of the FAM-labelled
aptamers. This could be improved by further assay optimisation, particularly the relative aptamer:
AuNP ratio.
Figure 2. Calibration graph for the determination of ampicillin in KPi Buffer using the initial
FAM-labelled aptamer assay. An increase in fluorescence is seenwith increasing ampicillin concentration
due to desorption of aptamers from the nanoparticle surface. The black, dashed line (at 3.75 µM)
corresponds to the limit of detection for the assay. Inset: Fluorescence intensities (λex = 487 nm and λem
= 528 nm) of ampicillin, cephalexin and amoxicillin samples at 1 mM concentrations, indicating the
aptamers selectivity for ampicillin over similarly structured β-lactamase molecules, and the hydrolysed
form of ampicillin. The error bars represent a single standard deviation from the mean. R2 value of
fitted line is 0.9848.
Based on previous methods to quantify the sensitivity of diagnostic assays, [51,52] we have
employed both the limit of the blank (LoB)—the minimum concentration that can be detected above a
blank sample containing no ampicillin, and the limit of detection (LoD)—the lowest concentration of
ampicillin that can be measured with statistical confidence. The LoB was determined to be 1.55 µM.
The LoD, based upon the minimum concentration measured plus a single standard deviation, was
slightly higher at 3.75 µM for the unoptimised assay in buffer. While the assay is therefore responsive
to ampicillin concentration, its application as a clinical assay where concentrations of ampicillin in
urine range from 1 µM to 1 mM, would be limited. The high limits of detection here are likely due
to inaccuracy at the lower end of the concentration range tested, and the larger variance seen in the
sample value, particularly at 10 nM concentrations.
The selectivity of the aptamer was also analysed here against the β-lactam antibiotics cephalexin
and amoxicillin, which are structurally similar to ampicillin. The enzymatically hydrolysed form
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of ampicillin was also compared, by first exposing ampicillin to a blend of β-lactamase enzymes,
the chemical structures of which can be seen in Figure 3. These measurements allowed for the
determination of whether the aptamer was selective for the overall molecular structure of ampicillin,
rather than the β-lactam ring structure or hydrolysed by-products. Solutions of cephalexin, amoxicillin,
and hydrolysed ampicillin (all at 1 mM) were prepared in KPi buffer and incubated with the preformed
AuNP-aptamer conjugate. As shown in the inset of Figure 2, a greater fluorescence signal, almost
double that of cephalexin, amoxicillin, or hydrolysed ampicillin, was obtained in the presence of
ampicillin. The aptamer therefore shows selectivity for the intact ampicillin over the structurally
similar antibiotics (cephalexin and ampicillin) or the hydrolysed form of ampicillin.
Figure 3. The chemical structures of ampicillin and its hydrolysed form resulting from the enzymatic
cleavage of the β-lactam ring structure.
Control assays were also performed using either only AuNP’s and varying concentrations of
ampicillin, or a non-selective ssDNA labelled with FAM (3′-TATGCGCCGGTTTTCAGCCT-5′-FAM)
incubated with AuNP’s and the varying concentrations of ampicillin, as per the assay. Negligible
fluorescence was observed for the blank assay without FAM labelled aptamer. When the non-selective
FAM labelled ssDNA strand was used instead of the aptamer, we observed no increase in fluorescence
with increasing concentrations of ampicillin (Supplementary Materials Figures S1 and S2).
2.2. FAM Labelled Aptamers for Use in Urine Based Assays
The pH of urine from healthy individuals can typically vary between pH 6 to 7. However, for
certain illnesses, including UTIs, the urine pH can vary between pH 4.5 to 8 [53]. The overall pH of the
urine sample was not expected to directly influence hydrolysis of the ampicillin, as over a short time
period (<10 days) the rate at which hydrolysis of ampicillin occurs has been shown to be independent
of pH, only the hydrolysis product created changes [54]. The fluoresence of fluorescein derivative
labels, such as FAM, however, are known to be affected by changes in pH [55]. Fluorescein itself has
a pKa value of 6.4 and is only recommended for use in a pH range between 5–7 [56]. Clinical urine
samples are typically collected and stored in tubes coated with boric acid (2% v/v) as a preservative to
maintain the sample prior to testing [57]. Critically, the boric acid also buffers the urine typically within
the range pH 6–8. To determine the efficacy of the FAM-labelled ampicillin aptamer assay over the
expected clinical range, dilutions of ampicillin in KPi buffer at pH 6–8 were prepared. The salt molarity
of the solution was maintained so as not to affect the isoelectric point of the AuNP and interfere with
the passive binding and desorption of the aptamer.
After the passive adsorption of the aptamer to the AuNPs, the aptamer-AuNP conjugates were
immediately incubated with ampicillin in KPi buffered at pH 6–8. As shown in Figure 4, the sensitivity
of the assay is optimal at pH 7, showing greater fluorescence intensities at lower concentrations, and
having a greater gradient of the calibration curve in the desired concentration range (100 nM to 1
mM). As expected with Fluorescein derivatives, the fluorescence intensity and gradient decrease at
pH 8, however the slope and intensities would still be sufficient for determination of the ampicillin
concentration in buffer at the desired clinical concentrations. Conversely, at pH 6 we observed a
significant reduction in fluorescence intensity, and the gradient of the curve was much shallower,
limiting the accuracy of the test at acidic pH. The LoDs determined from the lowest concentration
measured were found to be 9.16 µM, 2.18 µM, and 11.7 µM for pH 6, 7 and 8, respectively. While
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the curve gradient at pH 8 would allow it to function within the detection limit as a sensor, the LoD
is compromised. For use in a clinical setting, the assay would need to contain a buffering agent to
help buffer the pH of the assay after sample addition to an optimal pH 7, necessitating an additional
processing step over that typically used clinically for urine sample collection.
Figure 4. The effect of pH on the ampicillin aptamer assay was investigated using potassium phosphate
buffers with pH’s over the expected clinical range (pH 6–8). Due to the fluorescence tag employed, the
assays were expected to respond most effectively at neutral pH (pH 7), with a decrease in response
to the presence of ampicillin seen at pH 8 and pH 6. Inset: Limits of detection of the assay when
performed in different pH buffers. The lowest LoD (2.18 µM) was found to occur at pH 7. R2 values of
fitted lines are 0.9984, 0.9999, and 0.9999 for pH6, pH7 and pH8, respectively.
As with the initial attempt to determine ampicillin concentrations using the FAM labelled
aptamer strand, the higher than desired limits of detection are due to variance at the lower end of the
concentration range tested. This variance may not only occur due to the pH fluctuation, but also the
interference of ampicillin and its hydrolysed form which occurs at similar wavelengths to that of the
FAM fluorescent tag, as discussed below and shown in Figure 5.
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Figure 5. Normalised fluorescence emission spectra of the fluorescent dyes Alexafluor647 and FITC
(analogous with fluorescine (FAM)) used to label the aptamer strands compared with those of the
pooled urine samples, ampicillin and its hydrolysed form. The spectral overlap between the inherent
fluorescence of urine, ampicillin and its hydrolysed form with that of the FAM labelled aptamer can
be seen to seriously interfere with the signal from the FAM dye. This and the previously shown pH
stability of the flourescine based dyes further complicates the use of this dye in detecting ampicillin
in the pooled urine samples. The fluorescence of Alexafluor647 labelled aptamers is significantly
separated from that of the matrix components (urine, ampicillin and hydrolysed ampicillin) and thus
more suitable for the determination of ampicillin concentrations in clinical urine samples.
2.3. Development of Test to Determine Ampicillin Concentration in Urine
Development of a test that works in unprocessed urine samples necessitates a change of the
fluorescent label not only due to the pH sensitivity of the label but also the intrinsic fluorescence
exhibited by urine. This intrinsic fluorescence significantly overlaps that of the fluorescein based
fluorescent tags used in the previous work. The fluorescence of urine is due to the presence of
flavins, which are normally found in urine at low concentrations in healthy patients and exhibit a
fluorescence emission at approximately 520 nm [58]. As shown in Figure 5, the fluorescence of urine
overlaps spectrally with that of FAM but not Alexafluor647. The problem of spectral overlap is further
exacerbated by the presence of any hydrolysed ampicillin within the sample. While the aptamer-based
assay itself demonstrates some selectivity between hydrolysed and non-hydrolysed ampicillin, both
ampicillin and its hydrolysed products display an intrinsic fluorescence, which—depending on the
concentration—can interfere with that of the FAM label. β-Lactam antibiotics are readily hydrolysed
by β-lactamase enzymes, which are one of the main modes of resistance in drug resistant UTI’s [5,59].
β-Lactamase enzymes catalyse the hydrolysis of theβ-lactam ring structure resulting in the deactivation
of the antibiotic, and a change in the fluorescence spectrum.
Emission/excitation fluorescence spectra of the aptamer strands labelled with Alexafluor647
in undiluted urine samples were compared to those of unprocessed urine, FAM labelled aptamer,
ampicillin, and hydrolysed ampicillin at the required concentrations to identify regions of spectral
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overlap. Hydrolysed ampicillin was synthesised by exposure of a stock solution in KPi buffer at pH 7
to a blend of β-lactamase enzymes that was incubated at 37 ◦C for 48 h. The β-lactamase enzymes were
subsequently filtered from the samples under centrifugation with a 30 KDa filter and the hydrolysed
ampicillin collected and analysed using 1HNMR and mass spectroscopy to determine the degree of
hydrolysis (Supplementary Materials Figures S3–S6). After analysis, the resulting stock of hydrolysed
ampicillin was diluted to the required concentrations.
The emission excitation spectra of the FAM and Alexafluor647 bound aptamers, have
characteristically narrow emission spectra. Specifically, FAM fluorescence was found to occur between
360–400 nm when excited at 350 nm, and between 520–540 nm when excited at 450–500 nm. Similarly,
Alexafluor647 fluoresced at a single emission peak between 660–700 nm when excited at either 525 or
600–650 nm. This is in good agreement with the fluorescence spectra expected for these probes [56].
Urine samples used in this paper possess a broad fluorescence band between 350–600 nm when
excited at wavelengths between 300–500 nm. This overlaps directly with the fluorescent spectrum
of FAM. While ampicillin shows a broad fluorescence between 390 and 530 nm when excited at
wavelengths below 400 nm, upon hydrolysis this fluorescence shifts to longer wavelengths between 475
and 550 nm when excited at 425 nm, which was not present in the ampicillin spectra. The fluorescence
signals of Alexafluor647 are quite distinct and separate from any of the other fluorescent reagents
present within the sample matrix. 2D emission excitation spectra are shown in the Supplementary
Materials Figure S7.
Having established that the fluorescence spectra of Alexafluor647 can be distinguished from
competing fluorescent components within the assay and sample matrix, the sensitivity of the assay
using Alexafluor647-labelled ampicillin aptamer was assessed. Again, a dilution series of ampicillin
was prepared between 1 mM and 1 nM in both KPi Buffer (pH 7) and in filter-sterilised urine samples.
The aptamer-AuNP conjugate was incubated for 1 h at room temperature prior to addition of the
ampicillin samples which was then incubated for a further hour at room temperature, before the
fluorescence of the Alexafluor647 tag (at λEx = 640 nm, λEm = 681 nm) was quantified. The calibration
curve for the Alexafluor647-labelled ampicillin aptamer is shown in Figure 6.
Both the buffer and urine assay results show the standard assay response curve expected for
biochemical based assays, with the gradient of the slope maximised over the expected clinical range for
ampicillin concentrations in urine (100 nM to 100 µM) [60]. The urine-based assay shows only a slight
drop in fluorescence emission compared to that performed in buffer, presumably due to scattering
of the light in the urine matrix. The LoD, calculated from the minimum concentration of ampicillin
measured and its standard deviation, were found to be 43.8 nM and 20.6 nM for the buffer and urine
sample matrices, respectively. These LoD values suggest that the assay is suitable for use over the
desired clinical range. Typically, the maximum concentration of antibiotics in human urine is around
80 to 115 µg/mL (236 to 322 µM), dependent on the age and health of the patient [60]. The assay would
further prove suitable for monitoring of ampicillin levels used in veterinary practices where ampicillin
levels in urine excretions have been measured to be 309 ± 55 µg/mL (approx. 0.8 mM) after 8 h in
dogs [61]. Control assays can be found in the Supplementary Materials, Figures S8 and S9.
The short incubation time of 1 h coupled with the compatibility of the assay with conventional
96-well format fluorescence measurements would allow the technique to easily fit into current protocols
employed in both healthcare and veterinary practice, without the need for specialised equipment
or training.
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Figure 6. Fluorescence intensity for the Alexafluor647-labelled ampicillin aptamer assay when exposed
to varying concentrations of ampicillin in buffer and urine matrices. The LoD for ampicillin in KPi
buffer and unprocessed and unbuffered urine was found to be 43.8 nM and 20.6 nM, respectively.
The error bars in the figure represent a single standard deviation from the mean. R2 values for fitted
lines are 0.9674 and 0.9999 for the assay performed in buffer and urine, respectively.
3. Discussion
An aptameric-based assay has been demonstrated for the detection and quantification of ampicillin
in urine, using a fluorescently labelled AuNP-aptamer conjugate. By optimising the AuNP: aptamer
concentration ratio andfluorescent label, the assaywas shown to be less sensitive to interference from the
sample matrix and/or any hydrolysed β-lactams present within the clinical sample. The concentration
of ampicillin could be determined down to 43.8 nM and 20.6 nM in buffer and urine, respectively.
The determination of ampicillin concentrations to these levels meets those that would be required for
determination of ampicillin concentrations in clinical samples, which typically lie in the µM range,
depending on dose and excretion rate. Using this assay, the ampicillin concentration can be determined
within an hour of sample incubation; thus, it would be possible to use this test to allow for the
determination of optimal dosage and monitoring patients’ compliance with prescriptions.
The stability of the aptamer typically led to the assay being used within 28 days. However,
long-term stability studies are not within the scope of this work. After this time, it was seen
that reproducibility began to suffer and variance in the results increased, suggesting that the
fluorescently-labelled aptamer was not stable beyond this point.
As shown in Table 1, the aptamer-based assay presented here only requires a standard plate
and provides an effective way of measuring ampicillin concentration in urine samples, without any
prior sample processing. Whereas both HPLC and SERS analyses require specialised and expensive
equipment and usually a dedicated experienced operator.
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Table 1. Comparison of various techniques for the detection of β-lactam class antibiotics.
Technique Antibiotic
Sample
Matrix
Time
Taken
LoD
(µg/mL)
LoD (µM) %cv (%) [Ref]
Dip-stick inhibition Amoxycillin Urine
1 to 14
days
N/A ‡ N/A N/A [62]
HPLC with UV-Vis
detection
Various
β-lactams
Ampicillin
Plasma
1 to 25 min
*
4.0–197
4.8–130
11.4–563.81
3.7–372.1
0.4–6.8
0.7–6.5
[34]
UHPLC with UV-Vis
detection
Ampicillin Plasma 8 min * 0.5 1.4 0.03–1.8 [35]
HPLC-MS Ampicillin Plasma 13 min * 0.05–50 0.143–143.1 N/A [36,37]
Surface Enhanced Raman
Spectroscopy (SERS)
Ampicillin DI Water n/a 0.027 0.07 N/A [20,21]
Surface Enhanced Raman
Spectroscopy (SERS)
Ampicillin Buffer 20 min * 349 1000 N/A [20,22]
Fluorescently labelled
aptamer detection
Ampicillin Urine 60 min 0.007 0.026 1–9%
‡ indicates that the test uses an inhibition technique to determine the effectiveness of the antibiotic and therefore
does not give a concentration readout. * Indicates the time shown is the run time of the technique only not including
the additional sample preparation time.
4. Materials and Methods
Ampicillin was purchased from Sigma-Aldrich (A1593), cephalexin monohydrate was purchased
from Fluorochem (463365), and amoxicillin trihydrate purchased from Apollo Scientific (BIA0101), and
stored at 8 ◦C.
β-lactamase enzymes were purchased from Sigma-Aldrich (L7920), as a blend of recombinant
proteins, expressed in E. coli, which contains two individual β-lactamases (β-lactamase I (600–1500 IU
per vial) and β-lactamase II (60–150 IU per vial). β-lactamases were dissolved in KPi buffer (50 mM)
and stored in aliquots of β-lactamase I (60–1500 IU/mL) and β-lactamase II (6–15 IU/mL) at −20 ◦C.
The ampicillin specific DNA aptamer (3′-GCGGGCGGTTGTATAGCGG-5′) and control aptamers
(3′-TATGCGCCGGTTTTCAGCCT-5′-FAM) with their respective fluorescent labels were custom
synthesized by and purchased from Thermo Fisher Scientific (Life Technologies). The aptamer was
supplied modified with either a FAM or Alexafluor647 fluorescent tag modification to the 5′ end.
The lyophilised aptamers were dissolved to the required stock concentration using KPi buffer (100 mM,
pH 8) containing magnesium chloride (MgCl2, 10 mM) and stored at 8
◦C. The fluorescently labelled
aptamers, both the FAM and Alexa647 derivatives, were seen to be stable for over 28 days when
dissolved and aliquoted in KPi buffer (100 mM, pH 8) containing magnesium chloride (MgCl2, 10 mM)
and stored at 8 ◦C.
The AuNPs were synthesised according to the Turkevich method, using sodium citrate to reduce
HAuCl4 [63]. All chemicals were purchased from Sigma-Aldrich unless otherwise stated. A flask
containing AuClH4 (0.2% w/v, 7 mL) MQ water (43 mL) was heated to 110
◦C. Once the reaction
solution was boiling, trisodium citrate (6 mL of 1% w/v) was added. After 10 min the reaction mixture
had turned from colorless to red. The flask was then removed from the heating block and allowed to
return to room temperature. Analysis by UV-vis spectrometry determined the resulting solution to be
OD 9 with (λmax = 527 nm). The solution was further diluted with MQ water to give a final solution
of OD 0.9 and stored at 4 ◦C. The average particle diameter of the AuNPs was 13 nm, as determined by
UV/Vis Spectroscopy [64].
Urine samples were collected anonymously from 13 healthy adult volunteers that had not shown
symptoms of infection and had not taken antibiotics within 1 month prior to the sample collection.
Participants were recruited from within the University of York. Samples were filter sterilised using
0.22 µm syringe filters to remove any cells. The urine samples were combined to form an “average”
human urine pool which was aliquoted and stored in a −80 ◦C freezer. The pH of the resulting urine
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was measured to be pH 6.7 All collection and processing of the samples was performed and conforms
to the University of York’s Ethical approval and clinical sample handling guidelines.
4.1. Preparation of β-Lactam Antibiotic Solutions
β-lactam antibiotics (ampicillin, cephalexin, and amoxicillin) were prepared directly before use by
dissolving in KPi buffer (100 mM) to a stock concentration of 10 mM and stored at 8 ◦C until used. For
use in the assay, serial dilutions of the stock concentration of aptamer were prepared in KPi buffer (100
mM) at the required pH, between 1 nM and 10 mM.
4.2. Preparation of Hydrolysed β-Lactam Solutions
Hydrolysed forms of the β-lactam antibiotics (ampicillin, cephalexin, and amoxicillin) were
prepared by dissolving the drug in KPi buffer (100 mM, pH 7) to form stock solutions (10 mM). To 1
mL of antibiotic stock solution was added 100 µL β-lactamase blend (β-lactamase I (60–1500 IU/mL)
and β-lactamase II (6–15 IU/mL)) in KPi buffer (50 mM, pH 7). The solutions were then vortexed
and incubated for 48 h at 37 ◦C. β-lactamase enzymes were then removed from the solution using a
centrifugal filter (Amicon® Ultra 0.5 mL, Millipore (UK) Limited, Watford, UK) with a 30 KDa cut-off
and the hydrolysed β-lactam recovered. Hydrolysis of the β-lactam was confirmed by high resolution
mass spectrometry and 1H NMR.
For use in the assay, serial dilutions of the stock concentration of the hydrolysed β-lactam
antibiotics (10 mM) were prepared in KPi buffer (100 mM) at the required pH between 1 nM and
10 mM.
4.3. Determination of Ampicillin Concentrations in Buffer and Urine Using Aptamer Based Assay
Prior to use, the aptamers were denatured at 95 ◦C for 5 min before cooling to 4 ◦C, in 200 µL
aliquots of annealing buffer (100 mM KPi, 1 mM MgCl2, pH 8. The fluorescently labelled aptamer
was subsequently diluted from the stock to the desired concentration (10 nM and 100 nM for the FAM
and Alexafluor647 labelled aptamer strands, respectively) in KPi buffer (100 mM, pH 7) before a 50 µL
aliquot was incubated with the AuNP solution (Ø ≈ 13 nm, OD 0.9, 50 µL). Ampicillin in KPi buffer (100
mM, pH 7) was prepared at various concentrations between 1 mM and 1 nM by serial dilution before a
50 µL aliquot was mixed with the DNA-aptamer solution and incubated for 1 h at room temperature.
Fluorescence emission was recorded for each sample (each concentration analysed in triplicate)
using a Synergy H1 microplate reader (Biotek, UK). FAM labelled aptamers were measured at λex = 487
nm, λem = 528 nm while the emission intensity of the Alexafluor647 labelled aptamers was measured
at λex = 640 nm, λem = 681 nm.
4.4. Emission/Excitation Fluorescence Spectra
Fluorescence spectra of all β-lactam antibiotics (10 mM), and their hydrolysed forms (10 mM),
as well as urine, KPi Buffer (100 mM), AuNPs (OD 0.9) and fluorescently tagged aptamer ssDNA
(100 nM), were collected using a Synergy H1 microplate reader (Biotek, UK). Then, 100 µL of each
reagent solution was dispensed into a 96-well plate at the concentrations used in the assay. Emission
spectra were collected between λem = 300–700 nm at 10 nm intervals, the excitation wavelength was
varied between λex =300–700 nm at 25 nm intervals. Excitation spectra were collected between λex =
300–700 nm at 10 nm intervals, the emission wavelength was varied between λem = 300–700 nm at
25 nm intervals.
4.5. Preparation and Determination of Control Assays
The blank control assay, where no fluorescently labelled aptamer was performed by, taking 200 µL
aliquots of annealing buffer (100 mM KPi, 1 mM MgCl2, pH 8) and heating this to 95
◦C for 5 min
before cooling to 4 ◦C. This buffer was then incubated with the AuNP solution (Ø ≈ 13 nm, OD 0.9,
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50 µL), for 1 h at room temperature. Ampicillin in KPi buffer (100 mM, pH 7) was prepared at various
concentrations between 1 mM and 1 nM by serial dilution before a 50 µL aliquot was mixed with the
DNA-aptamer solution and incubated for 1 h at room temperature. This heating and cooling cycle is
standard and is included to remove misfolds in the aptamer structure [65].
Fluorescence emission was recorded for each sample (each concentration analysed in triplicate)
using a Synergy H1 microplate reader (Biotek, UK). FAM labelled aptamers were measured at λex
= 487 nm, λem = 528 nm while the emission intensity of the Alexafluor647-labelled aptamers was
measured at λex = 640 nm, λem= 681 nm.
For the control assay where a non-selective ssDNA strand labelled with FAM (3′-TATGCGCC
GGTTTTCAGCCT-5′-FAM) was used in place of the selective aptamer strand labelled with FAM,
the following procedure was used. Prior to use, the control aptamer was denatured at 95 ◦C for
5 min before cooling to 4 ◦C, in 200 µL aliquots of annealing buffer (100 mM KPi, 1 mMMgCl2, pH
8). The fluorescently labelled aptamer (3′-TATGCGCCGGTTTTCAGCCT-5′-FAM) was subsequently
diluted from the stock to the desired concentration (100 nM) in KPi buffer (100 mM, pH 7) before a
50 µL aliquot was incubated with the AuNP solution (Ø ≈ 13 nm, OD 0.9, 50 µL). Ampicillin in KPi
buffer (100 mM, pH 7) was prepared at various concentrations between 1 mM and 1 nM by serial
dilution before a 50 µL aliquot was mixed with the DNA-aptamer solution and incubated for 1 h at
room temperature.
Fluorescence emission was recorded for each sample (each concentration analysed in triplicate)
using a Synergy H1 microplate reader (BioTek UK, Swindon, UK). FAM labelled aptamers were
measured at λex = 487nm, λem = 528 nm.
5. Conclusions
In conclusion, the assay developed in this work can determine the concentration of the β-lactam
samples to as low as 20.6 nM directly from urine samples through the use of fluorescently-labelled
aptamer and standard plate reader within 1 h of sample addition, without the need for expensive
equipment or specialised personnel to interpret the results. By using a simple fluorescent assay, the
technique aligns well with conventional healthcare pathways within a clinical setting, rather than
requiring the development of new processes and equipment. These benefits would in turn allow for
more effective antibiotic use, helping to overcome the development of drug-resistant infections.
Supplementary Materials: The following are available online at http://www.mdpi.com/2079-6382/9/10/655/s1,
Figure S1: Blank control assay, performed at FAM fluorescence frequencies (λex = 487 nm, λem = 528 nm) when
no labelled aptamer is present and exposed to varying concentrations of ampicillin in buffer. The fluorescence
observed is negligible in comparison to that of the fluorescence when the aptamer is present, and no correlation
can be seen between the concentration of ampicillin and the fluorescence, Figure S2: Control Data for the assay
when using a FAM labelled control aptamer (not specific to ampicillin) in KPi buffer in the presence of varying
concentrations of ampicillin. There can be seen to be no correlation between the degree of fluorescence of the
assay and the concentrations of ampicillin, Figure S3: 1HNMR spectrum of Ampicillin in DMSO-d6 with β-lactam
protons labelled, Figure S4: Mass spectrometry analysis of Ampicillin in MeOH, Figure S5: 1H NMR spectrum of
Hydrolysed Ampicillin in DMSO-d6, Figure S6: Mass Spectrometry data for Hydrolysed Ampicillin in MeOH,
Figure S7: 2D fluorescence emission/excitation spectra of the main assay components. The broad fluorescence of
the Urine (a), ampicillin (b), and hydrolysed ampicillin (c) clearly overlap and interefere with that of the FAM
labelled aptamer strand (d). The Alexafluor647 labelled aptamers emission and excitation are clearly unaffected
by these, Figure S8: Blank Control data for final assay using the Alexafluor647 labelled aptamer (red) in buffer in
the presence of varying concentrations of ampicillin. Inset magnification to show levels of fluorescence present
when no Alexafluor647 labelled aptamer is present (blue). The levels of fluorescence can be seen to negligible in
comparison to that of the assay in the presence of ampicillin, Figure S9: Control data for final assay using the
Alexafluor647 labelled aptamer (green) in urine in the presence of varying concentrations of ampicillin. Inset
magnification to show levels of fluorescence present when no Alexafluor647 labelled aptamer is present (blue).
The levels of fluorescence can be seen to negligible in comparison to that of the assay in the presence of ampicillin.
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